CCO Independent Conference Highlights of the 2023 ASCO Gastrointestinal Cancers Symposium *

January 19-21, 2023; San Francisco, California
Read an expert preview commentary, download capsule summary slidesets, and read an expert analysis text module highlighting key studies from the 2023 ASCO Gastrointestinal Cancers Symposium.

Share

Program Content

9 Capsule Summary Slidesets

Activities

Pembro + Lenvatinib + CT for GEC
LEAP-015: Phase III Safety Run-in Data With Pembrolizumab + Lenvatinib + Chemotherapy for Advanced Gastroesophageal Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 25, 2023

Expires: January 24, 2024

View Activity
Zolbetuximab for CLDN18.2+ GEC
SPOTLIGHT: Phase III Study of First-line Zolbetuximab + mFOLFOX6 for Advanced CLDN18.2+/HER2- Gastric/Gastroesophageal Junction Adenocarcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 25, 2023

Expires: January 24, 2024

View Activity
Nab-Paclitaxel + Gem/Cis for BTCs
SWOG 1815: Phase III Trial of First-line Gemcitabine/Cisplatin ± Nab-Paclitaxel for Advanced Biliary Tract Cancers
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 26, 2023

Expires: January 25, 2024

View Activity
NALIRIFOX for mPDAC
NAPOLI 3: Phase III Trial of First-line NALIRIFOX vs Nab-Paclitaxel + Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 30, 2023

Expires: January 29, 2024

View Activity
TAS-102 ± Bev for Refractory mCRC
SUNLIGHT: Phase III Trial of TAS-102 With or Without Bevacizumab for Third-line Treatment of Refractory Metastatic Colorectal Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 30, 2023

Expires: January 29, 2024

View Activity
HER2 Scoring Systems in mCRC
Concordance Analysis of Gastric and Breast Cancer HER2 Scoring Systems for mCRC From the MOUNTAINEER Phase II Trial
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 30, 2023

Expires: January 29, 2024

View Activity
Pemigatinib in mCRC
Phase II Study of the FGFR Inhibitor Pemigatinib for Previously Treated Metastatic CRC With FGF/FGFR Alterations
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 30, 2023

Expires: January 29, 2024

View Activity
CheckMate 649 Update
CheckMate 649 Update: Phase III Study of First-line Nivolumab + CT vs CT for Advanced Gastric/GEJ Cancer and Esophageal Adenocarcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 30, 2023

Expires: January 29, 2024

View Activity
CheckMate 648 Update
CheckMate 648 Update: Phase III Study of First-line Nivolumab + CT vs Nivolumab + Ipilimumab vs CT for Advanced Esophageal Squamous Cell Carcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 02, 2023

Expires: February 01, 2024

View Activity

Activities

ASCO GI 2023: Key Studies
An Expert’s Guide to ASCO GI 2023: A Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: January 19, 2023

Expires: January 18, 2024

View Activity

Activities

Expert Analysis: ASCO GI 2023
CCO Independent Conference Highlights of the 2023 ASCO Gastrointestinal Cancers Symposium
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: March 23, 2023

Expires: March 22, 2024

View Activity

Faculty

cover img faculity

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

cover img faculity

Rachna Shroff, MD, MS

Professor of Medicine
Chief, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Bristol-Myers Squibb, Incyte Corporation, Merck Sharp & Dohme Corp, and Seagen Inc.

Bristol Myers Squibb

Incyte Corporation

Merck Sharp & Dohme Corp.

Seagen Inc.

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.